SCHEMBL3957937

SCHEMBL3957937

Cc1cc(Br)ccc1C(=O)NNc1ccc(F)c(C#N)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM4 Q14833 1/20 0.42
GAA P10253 5/20 0.41
NPC1 O15118 3/20 0.41
RAB9A P51151 3/20 0.41
ALDH1A1 P00352 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
LMNA P02545 1/20 0.41
KMT2A Q03164 1/20 0.41
KCNH2 Q12809 1/20 0.41
FLT1 P17948 1/20 0.40
FLT4 P35916 1/20 0.40
KDR P35968 1/20 0.40
GPR27 Q9NS67 1/20 0.39
S1PR3 Q99500 7/20 0.38
S1PR1 P21453 5/20 0.38
MAPT P10636 2/20 0.37
KDM4E B2RXH2 1/20 0.37
GFER P55789 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3951071 0.86 NPC1 (0.48) NPC1RAB9AFLT1FLT4KDR
SCHEMBL3951092 0.81 XDH (0.40) ALDH1A1SMN1; SMN2GPR27MAPTKDM4E
SCHEMBL3951033 0.80 XDH (0.38) GAANPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL27007635 0.73 NPC1 (0.62) GAANPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL27669762 0.72 ALDH1A1 (0.38) ALDH1A1LMNAKCNH2FLT1FLT4
SCHEMBL27669881 0.72 DGAT1 (0.37) GAANPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL5443752 0.71 GRM4 (0.47) GRM4ALDH1A1KCNH2
SCHEMBL21919186 0.70 GRM4 (0.44) GRM4ALDH1A1KCNH2
SCHEMBL24669477 0.69 RAB9A (0.53) GAANPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL2890266 0.69 CNR2 (0.50) GRM4GAANPC1RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7605171-B2 (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists MERCK & CO., INC. (US) 2009-10-20 US disclosed
EP-1697333-A4 (3,4-DISUBSTITUTED)PROPANOIC CARBOXYLATES AS S1P (EDG) RECEPTOR AGONISTS MERCK & CO INC (US) 2009-07-08 EP disclosed
US-20080249093-A1 (3,4-Disubstituted)Propanoic Carboxylates as Sip (Edg) Receptor Agonists MERCK & CO., INC. (US) 2008-10-09 US disclosed
EP-1697333-A1 (3,4-DISUBSTITUTED)PROPANOIC CARBOXYLATES AS S1P (EDG) RECEPTOR AGONISTS Merck & Co., Inc. (US) 2006-09-06 EP disclosed
WO-2005058848-A1 (3,4-DISUBSTITUTED)PROPANOIC CARBOXYLATES AS S1P (EDG) RECEPTOR AGONISTS MERCK & CO., INC. (US) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080249093-A1 (3,4-Disubstituted)Propanoic Carboxylates as Sip (Edg) Receptor Agonists S1PR1, S1PR3, S1PR5 GRM4 2297/4885GAA 3443/4885NPC1 1518/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.